KalVista Pharmaceuticals reported $13.7 million in net product revenue for the third quarter ended September 30, 2025, with cost of revenue at $1.2 million, including manufacturing and inventory overhead costs for EKTERLY after US approval. As of September 30, 2025, the company held approximately $309.2 million in cash, cash equivalents, and marketable securities, which, along with projected revenues from EKTERLY, are expected to fund the company through profitability. The US launch of EKTERLY is showing strong momentum, with 937 patient start forms received through October and increasing repeat prescriptions. EKTERLY was also launched in Germany, with initial orders indicating positive demand, and recently received regulatory approval in Australia. KalVista completed a $144 million convertible note offering during the period.